Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Ware, Kathryn E ^a   Marshall, Marianne E ^a   Heasley, Lydia R ^a   Marek, Lindsay ^a   Hinz, Trista K ^a   Hercule, Paula ^a   Helfrich, Barbara A ^a   Doebele, Robert C ^a   Heasley, Lynn E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FGFR2 PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; KERATINOCYTE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; COCULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 7; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 79955675804     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014117     Document Type: Article

References (35)

1. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, et al.(1997) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3: 515-522.
2. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, et al.(2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807.
3. Dancey JE, (2004) Predictive factors for epidermal growth factor receptor inhibitors-the bull's-eye hits the arrow. Cancer Cell 5: 411-415.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al.(2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
5. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, et al.(2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11: 397-405.
6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al.(2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
7. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW, (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101: 4611-4614.
8. Zhang X, Chang A, (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5: 209-217.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al.(2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
10. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, et al.(2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609-2619.
11. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, et al.(2009) Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75: 196-207.
12. Morgillo F, Lee HY, (2005) Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 8: 298-310.
13. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD, (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25: 843-854.
14. Eswarakumar VP, Lax I, Schlessinger J, (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149.
15. Gross AJ, Steinberg SM, Reilly JG, Bliss DP Jr, Brennan J, Le PT, Simmons A, Phelps R, Mulshine JL, Ihde DC, Johnson BE, (1993) Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 53: 67-74.
16. Berger W, Setinek U, Mohr T, Kindas-Mugge I, Vetterlein M, et al.(1999) Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 83: 415-423.
17. Chandler LA, Sosnowski BA, Greenlees L, Aukerman SL, Baird A, et al.(1999) Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer 81: 451-458.
18. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, et al.(2008) Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 7: 3408-3419.
19. Kuhn H, Kopff C, Konrad J, Riedel A, Gessner C, et al.(2004) Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer 44: 167-174.
20. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, et al.(2008) Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 14: 6014-6022.
21. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, et al.(2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4: 521-528.
22. Sun F, Xie Q, Ma J, Yang S, Chen Q, et al.(2009) Nuclear factor Y is required for basal activation and chromatin accessibility of fibroblast growth factor receptor 2 promoter in osteoblast-like cells. J Biol Chem 284: 3136-3147.
23. McDermott LA, Simcox M, Higgins B, Nevins T, Kolinsky K, et al.(2005) RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation. Bioorg Med Chem 13: 4835-4841.
24. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al.(2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
25. Xu AM, Huang PH, Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 70: 3857-3860.
26. Engelman JA, Janne PA, (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895-2899.
27. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
28. Ross AJ, Dailey LA, Brighton LE, Devlin RB, (2007) Transcriptional profiling of mucociliary differentiation in human airway epithelial cells. Am J Respir Cell Mol Biol 37: 169-185.
29. Lorch JH, Klessner J, Park JK, Getsios S, Wu YL, et al.(2004) Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem 279: 37191-37200.
30. Ulich TR, Yi ES, Longmuir K, Yin S, Biltz R, et al.(1994) Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 93: 1298-1306.
31. Whitsett JA, (2002) Intrinsic and innate defenses in the lung: intersection of pathways regulating lung morphogenesis, host defense, and repair. J Clin Invest 109: 565-569.
32. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, et al.(2009) Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119: 512-523.
33. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, et al.(2007) Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6: 1683-1691.
34. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C, (2006) Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319.
35. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, et al.(1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970.